|
|
|
|
The prospective multicenter NOA-03 trial, conducted by the Neuro-Oncology Working Group (NOA) of the German Cancer Society, was initiated to define the feasibility and efficacy of single-agent high-dose methotrexate therapy without concomita nt radiotherapy in immunocompetent patients with primary central nervous system lymphoma. The regimen was well tolerated, but, unlike previously reported results, the activity of high-dose methotrexate was only moderate. |
|